Bluebird Bio
Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.
TC BioPharm Limited is a clinical development company based in Edinburgh, United Kingdom, that focuses on the development, manufacture, and commercialization of innovative cell-based therapies for cancer and severe viral infections. The company's flagship product, ImmuniCell, is an autologous therapy that involves the expansion of patient-derived cells in cleanroom environments to create treatments for various tumor types and viral infections. TC BioPharm is advancing its research through Phase II/III clinical studies targeting renal cell carcinoma, non-small cell lung cancer, and melanoma. The company utilizes its proprietary allogeneic gamma delta T cell platform to create novel immunotherapy products aimed at improving patient health and quality of life. Additionally, TC BioPharm has formed strategic partnerships with Medinet, bluebird bio, and NIPRO Corporation to enhance its development capabilities. Founded in 2013, the company is committed to providing safer, more cost-effective, and durable therapies for patients in need.
Pregenen designs and engineers molecules critical to a new generation of cell-based therapies for unmet medical needs. They work with our partners to apply their tools, services and reagents to increase the reliability, efficacy and safety of a new wave of therapies harnessing the specificity and functional power of molecules and cells produced by the body.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.